Total Payments
$564,294
2024 Payments
$22,568
Companies
20
Transactions
496
Medicare Patients
1,401
Medicare Billing
$484,578
Payment Breakdown by Category
Other$445,189 (78.9%)
Travel$67,337 (11.9%)
Consulting$43,933 (7.8%)
Food & Beverage$7,482 (1.3%)
Research$330.00 (0.1%)
Education$23.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $445,189 | 192 | 78.9% |
| Travel and Lodging | $67,337 | 148 | 11.9% |
| Consulting Fee | $43,933 | 17 | 7.8% |
| Food and Beverage | $7,482 | 137 | 1.3% |
| Unspecified | $330.00 | 1 | 0.1% |
| Education | $23.80 | 1 | 0.0% |
Payments by Type
General
$563,964
495 transactions
Research
$330.00
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $243,794 | 231 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $160,562 | 138 | $0 (2023) |
| Bayer Healthcare Pharmaceuticals Inc. | $146,531 | 74 | $0 (2024) |
| Clovis Oncology, Inc. | $4,990 | 2 | $0 (2020) |
| Novartis Pharmaceuticals Corporation | $2,025 | 1 | $0 (2024) |
| Amgen Inc. | $2,008 | 2 | $0 (2021) |
| AstraZeneca Pharmaceuticals LP | $1,904 | 4 | $0 (2024) |
| GENZYME CORPORATION | $706.42 | 3 | $0 (2019) |
| PFIZER INC. | $422.25 | 5 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $419.18 | 4 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $22,568 | 41 | Janssen Biotech, Inc. ($16,548) |
| 2023 | $70,729 | 52 | Bayer Healthcare Pharmaceuticals Inc. ($48,977) |
| 2022 | $119,222 | 120 | Janssen Biotech, Inc. ($71,054) |
| 2021 | $64,570 | 43 | Janssen Biotech, Inc. ($40,056) |
| 2020 | $49,504 | 35 | Bayer HealthCare Pharmaceuticals Inc. ($24,731) |
| 2019 | $64,660 | 46 | Janssen Biotech, Inc. ($62,458) |
| 2018 | $99,885 | 89 | Janssen Scientific Affairs, LLC ($89,247) |
| 2017 | $73,157 | 70 | Janssen Scientific Affairs, LLC ($67,610) |
All Payment Transactions
496 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/20/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $26.15 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $122.90 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $29.81 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $62.56 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,524.00 | General |
| Category: Oncology | ||||||
| 10/09/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug) | Food and Beverage | In-kind items and services | $30.43 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,575.00 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | Cash or cash equivalent | $28.14 | General |
| Category: Oncology | ||||||
| 08/29/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $5.50 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 08/27/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Consulting Fee | Cash or cash equivalent | $2,025.00 | General |
| Category: Oncology | ||||||
| 08/14/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $2.61 | General |
| Category: Oncology | ||||||
| 08/12/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug), Odomzo | Food and Beverage | In-kind items and services | $22.09 | General |
| Category: Oncology | ||||||
| 08/07/2024 | Merck Sharp & Dohme LLC | LYNPARZA (Biological) | Food and Beverage | In-kind items and services | $26.24 | General |
| Category: ONCOLOGY | ||||||
| 08/05/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $128.75 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 07/18/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 06/27/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 06/21/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,524.00 | General |
| Category: Oncology | ||||||
| 06/05/2024 | PFIZER INC. | XTANDI (Drug), TALZENNA | Food and Beverage | In-kind items and services | $25.68 | General |
| Category: ONCOLOGY | ||||||
| 05/29/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug) | Food and Beverage | In-kind items and services | $24.82 | General |
| Category: Oncology | ||||||
| 04/18/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Travel and Lodging | In-kind items and services | $95.98 | General |
| Category: Oncology | ||||||
| 04/10/2024 | Bayer Healthcare Pharmaceuticals Inc. | Xofigo (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $381.00 | General |
| Category: Oncology | ||||||
| 04/10/2024 | SUN PHARMACEUTICAL INDUSTRIES INC. | YONSA (Drug) | Food and Beverage | In-kind items and services | $25.67 | General |
| Category: Oncology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| ENZALUTAMIDE CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $330.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 314 | 962 | $2.0M | $108,427 |
| 2022 | 6 | 387 | 1,128 | $2.4M | $136,813 |
| 2021 | 9 | 368 | 1,088 | $2.5M | $122,642 |
| 2020 | 9 | 332 | 955 | $2.3M | $116,696 |
Total Patients
1,401
Total Services
4,133
Medicare Billing
$484,578
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 43 | 379 | $1.5M | $50,907 | 3.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 113 | 331 | $283,998 | $34,004 | 12.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 44 | 79 | $75,840 | $11,820 | 15.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 31 | 31 | $42,160 | $5,944 | 14.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 32 | 44 | $22,352 | $3,206 | 14.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 39 | 79 | $20,719 | $2,317 | 11.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 12 | 19 | $2,356 | $229.68 | 9.7% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 61 | 470 | $1.9M | $66,201 | 3.5% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 85 | 194 | $186,240 | $29,102 | 15.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 108 | 252 | $216,216 | $27,081 | 12.5% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 38 | 38 | $51,680 | $7,396 | 14.3% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2022 | 62 | 131 | $32,750 | $3,763 | 11.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 33 | 43 | $21,844 | $3,271 | 15.0% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2021 | 66 | 529 | $2.1M | $75,731 | 3.5% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 74 | 164 | $140,712 | $17,662 | 12.6% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 38 | 65 | $62,400 | $10,501 | 16.8% |
| 96402 | Hormonal anti-neoplastic chemotherapy administration beneath the skin or into muscle | Office | 2021 | 67 | 161 | $40,250 | $4,594 | 11.4% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 22 | 22 | $29,920 | $4,335 | 14.5% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 38 | 52 | $26,416 | $3,890 | 14.7% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 30 | 54 | $6,426 | $2,963 | 46.1% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 21 | 28 | $4,928 | $2,354 | 47.8% |
| 99212 | Established patient outpatient visit, total time 10-19 minutes | Office | 2021 | 12 | 13 | $4,602 | $611.52 | 13.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2020 | 62 | 497 | $2.0M | $84,894 | 4.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 62 | 123 | $105,534 | $11,089 | 10.5% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 43 | 59 | $56,640 | $7,079 | 12.5% |
About Dr. Matthew Rettig, MD
Dr. Matthew Rettig, MD is a Medical Oncology healthcare provider based in Los Angeles, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2006. The National Provider Identifier (NPI) number assigned to this provider is 1487751798.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Matthew Rettig, MD has received a total of $564,294 in payments from pharmaceutical and medical device companies, with $22,568 received in 2024. These payments were reported across 496 transactions from 20 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($445,189).
As a Medicare-enrolled provider, Rettig has provided services to 1,401 Medicare beneficiaries, totaling 4,133 services with total Medicare billing of $484,578. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Medical Oncology
- Other Specialties Urology, Hematology & Oncology
- Location Los Angeles, CA
- Active Since 09/20/2006
- Last Updated 01/09/2020
- Taxonomy Code 207RX0202X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1487751798
Products in Payments
- ERLEADA (Drug) $167,233
- Erleada (Drug) $162,082
- Nubeqa (Drug) $115,224
- DARZALEX (Biological) $64,856
- Xofigo (Drug) $27,047
- Rubraca (Drug) $4,990
- Vitrakvi (Drug) $4,260
- PLUVICTO (Drug) $2,025
- NO PRODUCT DISCUSSED (Drug) $1,126
- XTANDI (Drug) $422.25
- LYNPARZA (Drug) $254.27
- ZYTIGA (Drug) $232.74
- PROVENGE (Drug) $215.31
- Xtandi (Drug) $139.52
- YONSA (Drug) $123.45
- Bard Urinary Drainage Bag (Device) $47.68
- KEYTRUDA (Biological) $33.80
- FOTIVDA (Drug) $29.20
- LYNPARZA (Biological) $26.24
- XPOVIO (Drug) $23.80
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Medical Oncology Doctors in Los Angeles
Dr. Jacek Pinski, M.d, M.D
Medical Oncology — Payments: $882,931
Medical Oncology $882,931
Stephen Liu, Md, MD
Medical Oncology — Payments: $792,850
Medical Oncology $792,850
Mark Agulnik, Md, MD
Medical Oncology — Payments: $414,988
Medical Oncology $414,988
Dr. David Quinn, M.d, M.D
Medical Oncology — Payments: $304,638
Medical Oncology $304,638
Dr. David Tran, Md Phd, MD PHD
Medical Oncology — Payments: $131,074
Medical Oncology $131,074
Dr. Barbara Gitlitz, M.d, M.D
Medical Oncology — Payments: $68,433
Medical Oncology $68,433